Ueno, M., Finn, R. S., Ren, Z., Yau, T., Klümpen, H., Chan, S. L., . . . Zhao, H. (2023). Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): A randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet (British edition), 401(10391), 1853-1865. https://doi.org/10.1016/S0140-6736(23)00727-4
Citace podle Chicago (17th ed.)Ueno, Makoto, et al. "Pembrolizumab in Combination with Gemcitabine and Cisplatin Compared with Gemcitabine and Cisplatin Alone for Patients with Advanced Biliary Tract Cancer (KEYNOTE-966): A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial." The Lancet (British Edition) 401, no. 10391 (2023): 1853-1865. https://doi.org/10.1016/S0140-6736(23)00727-4.
Citace podle MLA (9th ed.)Ueno, Makoto, et al. "Pembrolizumab in Combination with Gemcitabine and Cisplatin Compared with Gemcitabine and Cisplatin Alone for Patients with Advanced Biliary Tract Cancer (KEYNOTE-966): A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial." The Lancet (British Edition), vol. 401, no. 10391, 2023, pp. 1853-1865, https://doi.org/10.1016/S0140-6736(23)00727-4.